Biohaven Ltd. logo

Biohaven Ltd.

BHVN

NYSEHealthcareBiotechnology

Latest quote

$13.77

−$0.095 · -0.69%

Aug 24, 10:13 AM ET

BHVN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

65

Gaining

Sentiment

44

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Vladimir Coric
Listed since
Sep 23, 2022
Employees
274

Market position

Volume
196.73K
0.08× average
Average volume
2.57M
Average daily volume
Market cap
2.07B USD
Beta
3.16
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.27B USD
EV / EBITDA
-1.75×
Earnings yield
-60.80%
Free cash flow yield
-50.21%

Profitability & efficiency

Return on equity
-1418.85%
Return on assets
-163.66%
Return on invested capital
-218.41%

Financial health

Current ratio
3.18×

Earnings

EPS beat rate
18%
2 beats, 7 misses, 2 met estimates
Average EPS surprise
-22.01%
11 comparable reports
Latest EPS result
-0.91
Estimate -0.76 · Miss by 19.58%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.65-1.19-1.74-2.28Q1 '25MissQ2 '25MissQ3 '25MetQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual -1.85, estimate -1.56, surprise -18.59%, Miss. Q2 2025, reported May 12, 2025: actual -2.17, estimate -1.67, surprise -29.94%, Miss. Q3 2025, reported Aug 11, 2025: actual -1.94, estimate -1.94, surprise 0.00%, Met estimate. Q4 2025, reported Nov 10, 2025: actual -1.64, estimate -1.91, surprise +14.14%, Beat. Q1 2026, reported Mar 2, 2026: actual -1.21, estimate -1.22, surprise +0.82%, Beat. Q2 2026, reported May 4, 2026: actual -0.88, estimate -0.86, surprise -2.33%, Miss. Q3 2026, reported Aug 10, 2026: actual -0.91, estimate -0.761, surprise -19.58%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.79, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates773.03K592.01K411K229.98KQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q3 2025, reported Aug 11, 2025: actual —, estimate 412.6K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 10, 2025: actual —, estimate 375.09K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 2, 2026: actual —, estimate 400K USD, surprise —, Comparison unavailable. Q2 2026, reported May 4, 2026: actual —, estimate 267.44K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual —, estimate 490.49K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 9, 2026: actual —, estimate 735.58K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

25 ratings
Strong buy00%
Buy1768%
Hold728%
Sell14%
Strong sell00%

BHVN news

BHVN peers

ETFs holding BHVN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BHVN

research.disclaimer